Precision Medicine Could Yield Significant Cost Savings in RA Treatment – Managed Markets Network

Nearly 90% of the first-line biologics that patients with RA receive are anti-TNF therapy, and research has found that the majority will fail to satisfy the ACR50 criteria, which is a 50% or greater improvement in disease activity,.. .

source website